Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Largest Pharma Promoter CMS Outpaced Market With Unique Specialty Pharma Focus

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China Medical System Holdings, the largest third-party promotion service company in China, differs from its competitors by targeting small- and mid-size specialty pharma as clients, giving the company more secure contracts, higher profile products and bigger margins

You may also be interested in...



AstraZeneca Offloads Two Mature CV Drugs For $500m

China Medical System has agreed to pay a total of $500m for selected rights to two mature AstraZeneca cardiovascular products, with the divestments set to provide new growth prospects for the Chinese firm while helping the UK-based multinational focus on innovative products in its second-largest global market.

Chinese Pharma Companies Target County-level Hospitals: China Earnings Roundup (Part 2)

PharmAsia News takes a closer look at how China’s largest third-party promotion company and second-largest domestic pharma have responded to price cuts and hospital reform.

Vaccines Shakeup Continues In China: NT Pharma Backs Away From GSK

SHANGHAI - China's largest vaccine distributor China NT Pharma Group announced Aug. 17 it will not renew its master distribution contract with its largest customer GlaxoSmithKline PLC, in part, it appears, due to burdens created by the new China Pharmacopeia that was issued at the end of 2010

Related Content

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel